Long-Term Survival in Cerebral Glioblastoma. Case Report and Critical Review of the Literature

1998 ◽  
Vol 84 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Fabrizio Puzzilli ◽  
Andrea Ruggeri ◽  
Luciano Mastronardi ◽  
Domenica Di Stefano ◽  
Pierpaolo Lunardi
Keyword(s):  
Glioblastoma Multiforme ◽  
Multimodal Therapy ◽  
Term Survival ◽  
Disease Free Interval ◽  
Average Survival ◽  
Younger Age ◽  
Aggressive Tumor ◽  
Long Term Survivors ◽  
Disease Free

Glioblastoma multiforme is the most malignant tumor of the glial series. The average survival of patients with this tumor ranges from 6 to 12 months. The case of a patient who survived for more than 11 years after diagnosis of a temporal-occipital glioblastoma which was treated with surgery, radiotherapy and chemotherapy is described. The authors deduce that among patients with glioblastoma multiforme (GM), those with a long disease-free interval after initial diagnosis who undergo multimodal therapy, including aggressive tumor removal, are the most likely long-term survivors (LS). Other factors which appeared to be related to longer survival were younger age and high Karnofsky scores.

The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme

2004 ◽  
Vol 101 (2) ◽  
pp. 219-226 ◽  
Author(s):  
Naoki Shinojima ◽  
Masato Kochi ◽  
Jun-Ichiro Hamada ◽  
Hideo Nakamura ◽  
Shigetoshi Yano ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Giant Cell ◽  
Adult Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Content Type ◽  
Free Interval ◽  
Younger Age ◽  
Fine Print

Object. Glioblastoma multiforme (GBM) remains incurable by conventional treatments, although some patients experience long-term survival. A younger age, a higher Karnofsky Performance Scale (KPS) score, more aggressive treatment, and long progression-free intervals have been reported to be positively associated with long-term postoperative patient survival. The aim of this retrospective study was the identification of additional favorable prognostic factors affecting long-term survival in surgically treated adult patients with supratentorial GBM. Methods. Of 113 adult patients newly diagnosed with histologically verified supratentorial GBM who were enrolled in Phase III trials during the period between 1987 and 1998, six (5.3%) who survived for longer than 5 years were defined as long-term survivors, whereas the remaining 107 patients served as controls. All six were women and were compared with the controls; they were younger (mean age 44.2 years, range 31–60 years), and their preoperative KPS scores were higher (mean 85, range 60–100). Four of the six patients underwent gross-total resection. In five patients (83.3%) the progression-free interval was longer than 5 years and in three a histopathological diagnosis of giant cell GBM was made. This diagnosis was not made in the other 107 patients. Conclusions. Among adult patients with supratentorial GBM, female sex and histopathological characteristics consistent with giant cell GBM may be predictive of a better survival rate, as may traditional factors (that is, younger age, good KPS score, more aggressive resection, and a long progression-free interval).

scholarly journals A rare case of anaplastic thyroid carcinoma in a young woman with prolonged survival

2013 ◽  
Vol 60 (4) ◽  
pp. 99-101
Author(s):  
Katarina Tausanovic ◽  
Vladan Zivaljevic ◽  
Ivan Paunovic ◽  
Aleksandar Diklic ◽  
Nevena Kalezic ◽  
...  
Keyword(s):  
Rare Case ◽  
Multimodal Therapy ◽  
Anaplastic Thyroid Cancer ◽  
The Elderly ◽  
Anaplastic Thyroid Carcinoma ◽  
Human Medicine ◽  
Term Survival ◽  
Average Survival ◽  
Aggressive Tumors

Anaplastic thyroid cancer (ATC) is one of the most aggressive tumors in human medicine. Despite the multimodal therapy, the average survival of patients is just several months. Fortunately, it is an extremely rare tumor. Most frequently, ATC occurs in the elderly, with the average age of the patients being almost 70 years. It is extremely rare that ATC occurs in people under the age of 40. We report a case of a 33 year old woman with ATC, with the diameter of the tumor being 8x7cm, confirmed by histopathology and imunohistochemistry. In January 2001, a total thyroidectomy was performed, and the tumor was completely resected. Postoperatively, the patient received radiation therapy. Ten years after the surgery, on regular check-ups, the patient is still living and there is no evidence of a recurrent tumor or metastases. This case is instructive for two reasons, as it shows that ATC can occur in younger people and that there is a possibility of long term survival.

Survival and long-term toxicities of biochemotherapy for metastatic melanoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8553-8553
Author(s):  
D. R. Minor ◽  
J. Miller ◽  
M. Kashani-Sabet
Keyword(s):  
Residual Disease ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
High Dose ◽  
Consecutive Series ◽  
Term Survival ◽  
Free Survival ◽  
Long Term Survivors ◽  
Disease Free

8553 Purpose: Because long-term survival after therapy for advanced stage IV melanoma is rare, we thought it would be useful to examine our series of survivors treated with biochemotherapy for melanoma to analyze the characteristics of survivors and their chronic toxicities. Patients and Methods: We reviewed our previously reported (J Clin Oncol. 2005:23:16s suppl, abstract 7547) consecutive series of 38 patients treated between 9/02 and 7/04. They received 6 cycles of inpatient temozolomide, cisplatin, vinblastine, decrescendo high- dose iv IL-2 , and interferon followed by maintenance immunotherapy using IL-2 and sargramostim using the O’Day regimen (Clinical Cancer Res. 2002:8:2775).Two of the ten long-term survivors received surgery for resection of residual disease after achieving a partial response with biochemotherapy. Maintenance immunotherapy was given for 6 to 24 months after biochemotherapy. Results: The median progression- free survival was 7.3 months. No patient developed progression later than 17 months after the start of therapy with the progression-free survival curve level at 24%. Median overall survival was 16.2 months. 10 of the 38 patients are alive and disease-free off therapy after an average of 3.3 years follow-up. Durable complete responses were seen in visceral sites including lung, bone, and pericardium, with 8 of 10 long- term survivors having M1B or M1C disease. 3 patients have significant lymphedema related to prior surgery, radiation therapy, or both. 2 patients, one with pre-existing diabetes, have significant persisting neuropathy. 5 of the 10 patients are hypothyroid. Menstrual function returned in the three women under age 45 in this study. Conclusion: This series supports the findings from other series that biochemotherapy, like high-dose IL-2, can give prolonged disease-free survival. Survivors have a high incidence of hypothyroidism but neuropathy and lymphedema, which affected a minority of patients, were the most bothersome long-term toxicities. No significant financial relationships to disclose.

scholarly journals Prognostic Factors in the Decision-Making Process for Sigmoid Volvulus. Results of a Single-Centre Retrospective Cohort Study.

2021 ◽  
Author(s):  
Zoe Slack ◽  
Mohamed Shams ◽  
Raheel Ahmad ◽  
Roshneen Ali ◽  
Diandra Antunes ◽  
...  
Keyword(s):  
Operative Management ◽  
Functional Condition ◽  
Sigmoid Volvulus ◽  
Definitive Treatment ◽  
Rectal Tube ◽  
Term Survival ◽  
Average Survival ◽  
Younger Age ◽  
Non Operative Management

Abstract BACKGROUND: Sigmoid volvulus is a common cause of emergency surgical admission. It often affects older males who are institutionalized and are less suitable surgical candidates. Definitive treatment is surgical, but first line treatment is via endoscopic devolution with or without placement of a rectal tube. After non-operative management recurrence is likely and carries a high mortality, therefore an early surgical approach may be considered in patients who are fit for surgery. We have retrospectively analyzed a cohort of patients with sigmoid volvulus in order to clarify if and when a more aggressive management is indicated.METHODS: We have reviewed data on admitted patients diagnosed with sigmoid volvulus over a 2-year period. Demographic, clinical data, morbidity and mortality were recorded in a database. The primary endpoint was patient survival. Secondary endpoint was the estimation of the factors that condition surgical choice.RESULTS: We analysed 332 admission of 78 patients. 39.7% of patients underwent surgical resection. The average survival was 54.9±8.8 months from the first hospitalization, irrespective of the treatment. Long-term survival was positively influenced by being female, having a low "social score", a younger age and surgery. Multivariate analysis showed that only being female and surgery were independently associated with better survival.CONCLUSION: Early surgery may be the best approach in patients with recurrent sigmoid volvulus, as it ensures longer survival with a better quality of life, regardless of the patient's social and functional condition.

scholarly journals Long-term survival following resection of extracompartmental osteosarcoma of the spine – A case report and literature review

2021 ◽  
Vol 12 ◽  
pp. 545
Author(s):  
Suresh S. Pillai
Keyword(s):  
Spine Surgery ◽  
Tumor Resection ◽  
Axial Skeleton ◽  
Sensory Level ◽  
Case Description ◽  
Term Survival ◽  
Long Term Survivors ◽  
Disease Free

Background: Osteosarcoma, representing 3% of sarcomas, rarely involves the axial skeleton. The overall 5-year survival is just 18%. Here, we present a 15-year-old female with an extracompartmental osteosarcoma, who following radical spine surgery, chemotherapy, and intensive radiotherapy remained disease-free 15.5 years later. Case Description: A 15-year-old female presented with an acute right lower extremity monoparesis and T4 relative sensory level attributed to a T4 extracompartmental Osteosarcoma. Following circumferential spine surgery, chemotherapy, and radiotherapy, her tumor did not recur over the 15.5-year follow-up period. Conclusion: Osteosarcoma rarely presents focally in the spine. When it originates in the spine, there are typically few long-term survivors. Here, we report a 15-year-old female who presented with an acute monoparesis attributed to an extracompartmental T4 spinal osteosarcoma. Following circumferential tumor resection, adjuvant chemotherapy, and radiotherapy, the patient remains disease-free 15.5 years later.

Metastatic Renal Cell Carcinoma Mimicking a Meningioma

Neurosurgery ◽  
1983 ◽  
Vol 13 (4) ◽  
pp. 430-434 ◽  
Author(s):  
K. Killebrew ◽  
M. Krigman ◽  
M. S. Mahaley ◽  
J. H. Scatliff
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Term Survival ◽  
Disease Free Interval ◽  
Free Interval ◽  
Solitary Metastases ◽  
Disease Free

Abstract We report a patient with renal cell carcinoma metastatic to the left trigone, which mimicked an intraventricular meningioma. The metastasis was recognized 13 years after removal of the primary tumor, a longer disease-free interval than any previously reported cases with brain metastases of renal cell carcinoma. The patient is now free of disease 4 years after resection and 17 years after the discovery of the primary tumor. Metastatic disease should be considered in all patients with prior resection of renal cell carcinoma who experience the onset of neurological disease, even after a prolonged disease-free interval. Long term survival is observed after the resection of solitary metastases, particularly if these appear after a prolonged disease-free interval.

scholarly journals Lymph node micrometastases detected by carcinoembryonic antigen mRNA affect long-term survival and disease-free interval in early-stage lung cancer patients

2012 ◽  
Vol 4 (5) ◽  
pp. 1140-1144 ◽  
Author(s):  
MARIO NOSOTTI ◽  
ALESSANDRO PALLESCHI ◽  
LORENZO ROSSO ◽  
DAVIDE TOSI ◽  
LUIGI SANTAMBROGIO ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Term Survival ◽  
Disease Free Interval ◽  
Lung Cancer Patients ◽  
Free Interval ◽  
Disease Free ◽  
Stage Lung Cancer

Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy

1998 ◽  
Vol 89 (1) ◽  
pp. 60-68 ◽  
Author(s):  
Richard B. Schwartz ◽  
B. Leonard Holman ◽  
Joseph F. Polak ◽  
Basem M. Garada ◽  
Marc S. Schwartz ◽  
...  
Keyword(s):  
Survival Rate ◽  
Glioblastoma Multiforme ◽  
Single Photon ◽  
Photon Emission ◽  
High Dose ◽  
Term Survival ◽  
Content Type ◽  
Dual Isotope ◽  
Fine Print

Object. The study was conducted to determine the association between dual-isotope single-photon emission computerized tomography (SPECT) scanning and histopathological findings of tumor recurrence and survival in patients treated with high-dose radiotherapy for glioblastoma multiforme. Methods. Studies in which SPECT with 201Tl and 99mTc-hexamethypropyleneamine oxime (HMPAO) were used were performed 1 day before reoperation in 47 patients with glioblastoma multiforme who had previously been treated by surgery and high-dose radiotherapy. Maximum uptake of 201Tl in the lesion was expressed as a ratio to that in the contralateral scalp, and uptake of 99mTc-HMPAO was expressed as a ratio to that in the cerebellar cortex. Patients were stratified into groups based on the maximum radioisotope uptake values in their tumor beds. The significance of differences in patient gender, histological characteristics of tissue at reoperation, and SPECT uptake group with respect to 1-year survival was elucidated by using the chi-square statistic. Comparisons of patient ages and time to tumor recurrence as functions of 1-year survival were made using the t-test. Survival data at 1 year were presented according to the Kaplan—Meier method, and the significance of potential differences was evaluated using the log-rank method. The effects of different variables (tumor type, time to recurrence, and SPECT grouping) on long-term survival were evaluated using Cox proportional models that controlled for age and gender. All patients in Group I (201Tl ratio < 2 and 99mTc-HMPAO ratio < 0.5) showed radiation changes in their biopsy specimens: they had an 83.3% 1-year survival rate. Group II patients (201T1 ratio < 2 and 99mTc-HMPAO ratio of ≥ 0.5 or 201Tl ratio between 2 and 3.5 regardless of 99mTc-HMPAO ratio) had predominantly infiltrating tumor (66.6%); they had a 29.2% 1-year survival rate. Almost all of the patients in Group III (201Tl ratio > 3.5 and 99mTc-HMPAO ratio ≥ 0.5) had solid tumor (88.2%) and they had a 6.7% 1-year survival rate. Histological data were associated with 1-year survival (p < 0.01); however, SPECT grouping was more closely associated with 1-year survival (p < 0.001) and was the only variable significantly associated with long-term survival (p < 0.005). Conclusions. Dual-isotope SPECT data correlate with histopathological findings made at reoperation and with survival in patients with malignant gliomas after surgical and high-dose radiation therapy.

Aggressive Treatment in Glioblastoma: What Determines the Survival of Patients?

2020 ◽  
Author(s):  
Lei Yu ◽  
Guozhong Zhang ◽  
Songtao Qi
Keyword(s):  
Overall Survival ◽  
Malignant Gliomas ◽  
Epidemiological Studies ◽  
Control Cohort ◽  
Poor Overall Survival ◽  
Term Survival ◽  
Significant Difference ◽  
Positive Rate ◽  
Long Term Survivors

Abstract Background and Study Aims The exact reason of long-term survival in glioblastoma (GBM) patients has remained uncertain. Molecular parameters in addition to histology to define malignant gliomas are hoped to facilitate clinical, experimental, and epidemiological studies. Material and Methods A population of GBM patients with similar clinical characteristics (especially similar resectability) was reviewed to compare the molecular variables between poor (overall survival [OS] < 18 months, control cohort) and long-term survivors (overall survival > 36 months, OS-36 cohort). Results Long-term GBM survivors were younger. In the OS-36 cohort, the positive rate of isocitrate dehydrogenase (IDH) mutation was very low (7.69%, 3/39) and there was no statistical difference in OS between IDH mutant and wild-type patients. The results of 1p/19q codeletions are similar. Besides, there were no significant difference in MGMT promoter methylation, telomerase reverse transcriptase (TERT) promoter mutation, and TP53 mutations between OS-36 cohort and control cohort. Conclusions No distinct markers consistently have been identified in long-term survivors of GBM patients, and great importance should be attached to further understand the biological characteristics of the invasive glioma cells because of the nature of diffuse tumor permeation.

scholarly journals Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival

Cureus ◽  
2021 ◽  
Author(s):  
Omar Rabab'h ◽  
Ali Al-Ramadan ◽  
Jawad Shah ◽  
Hugo Lopez-Negrete ◽  
Abeer Gharaibeh
Keyword(s):  
Glioblastoma Multiforme ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document